Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03274453
Other study ID # 12-02202
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date November 1, 2012
Est. completion date September 2017

Study information

Verified date May 2018
Source New York University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the proposed study is to examine the effectiveness of low dose postoperative ketamine infusion as an analgesic adjuvant to morphine pca in opioid tolerant and opioid naïve patients after major spine surgery. Primary endpoints of the study are to determine the effectiveness of postoperative ketamine infusion in for the reduction of postoperative pain and opioid requirements.


Description:

Subjects aged 16 to 75, ASA I to III, scheduled for an elective lumbar fusion surgery of at least two levels under general anaesthesia, were prospectively studied. We defined opioid-tolerant as the daily use of opioid pain medication (oxycodone, morphine, hydromorphone, fentanyl, methadone, or tramadol) during the two weeks before surgery. Patients who did not fulfil that criterion were deemed to be opioid-naïve. Exclusion criteria were poorly controlled hypertension, severe cardiac or pulmonary disease, elevated intraocular pressure, severe hepatic or renal dysfunction, pregnancy, a history of psychiatric disorder, inability to speak English, inability to understand the numerical pain scale or to operate the patient-controlled analgesia pump, and known allergy to ketamine or hydromorphone.

Patients were allocated to the opioid-naïve or opioid-tolerant arm as defined above, and subsequently randomized into two groups, for a total of 4 groups: the opioid-naïve ketamine, the opioid-naïve placebo, the opioid-tolerant ketamine, and the opioid-tolerant placebo. Patients in each group were randomized to receive either a ketamine infusion (ketamine bolus 0.2 mg/kg over 30 minutes, started on arrival in post-anesthesia care unit (PACU), followed by a fixed-rate infusion of 0.12 mg/kg/h for 24 hours), or placebo (identical volume/rate of normal saline). Randomization within each group was performed by the study coordinator using a computer-generated random number list in a 1:1 ratio. Study medication and placebo were produced according to the randomization list in identical and consecutively numbered 250 mL bags. The pharmacist was not involved in patient care. Information about treatment was concealed but available for unblinding in case of acute complications. During the entire study period investigators performing the postoperative assessments, medical staff (nurse, anesthesiologist, and surgeon), and subjects were blinded to group allocation.

In all patients, general anesthesia was induced with propofol based on patient weight. Rocuronium 0.6 - 1.2 mg/kg was used to facilitate endotracheal intubation. Anesthesia was maintained with propofol (variable rate to maintain bispectral index (BIS) at a level acceptable for surgical anesthesia), desflurane <1.5% mixed of air and oxygen, fentanyl, sufentanil, hydromorphone and morphine at the discretion of the anesthetic staff. Blood pressure was maintained within 20% of baseline, and hypotension was treated at the discretion of the anesthetic staff with isotonic sodium chloride solution, hetastarch, ephedrine and phenylephrine intravenously.

Most patients received 1000 mg of IV acetaminophen at the end of surgery (see Table 2). NSAIDs were not used in the immediate perioperative period because of the surgeons' concern that they might impede bone healing and proper fusion.

For all patients, postoperative pain treatment during the first 24 hours consisted of standard care of IV patient controlled analgesia (PCA) with hydromorphone (0.2 mg/dose, lockout 6 min, maximum 2 mg/h), started on arrival in PACU. Preoperatively, the patients were educated by the nursing staff in the use of the PCA pump and the numerical pain scale. Rescue medication of IV hydromorphone 0.2 to 0.3 mg as needed was administered by a nurse with the goal to reduce the numerical pain score (NPS; 0 = no pain, 10 = worst imaginable pain) below 4. Opioid pain medication was restricted to hydromorphone in order to allow for valid comparison between the groups. After 24 hours, the PCA was discontinued and all patients were treated according to the surgical department's standard regimen. Diazepam 2 mg IV was administered for severe muscle spasms as needed.

Moderate to severe nausea or vomiting was treated with IV ondansetron 4 mg. If ondansetron was ineffective, IV metoclopramide 10 mg was administered.

All postoperative assessments were performed by the study investigators or trained nurses blinded to group allocation. Cumulative IV hydromorphone consumption was calculated from 0 to 24 hours postoperatively. NPS were recorded at arrival to PACU, then every 30 min during the first 2 hours, and then every 2 hours on the floor during the first 24 hours after surgery while patients were awake.

The primary outcome was cumulative hydromorphone consumption during the first 24h after surgery. Secondary outcome was NPS in the same time period. We also recorded central nervous system adverse events during the same period.


Recruitment information / eligibility

Status Completed
Enrollment 129
Est. completion date September 2017
Est. primary completion date November 1, 2014
Accepts healthy volunteers No
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria:

- Adult and teenage (>/=16) male or female who will undergo surgery for multilevel (>4 level) spinal fusion from a posterior approach with general anesthesia, and who are fluent English speakers such that they can complete the pain score and satisfaction questionnaires whose scores are a critical outcome variable.

- If female, subject is non-lactating and is either:

- Not of childbearing potential

- Of childbearing potential but is not pregnant at time of baseline as determined by pre-surgical pregnancy testing.

- Subject is ASA physical status 1, 2, or 3.

Exclusion Criteria:

- anxiety

- psychiatric disorder

- Allergy or sensitivity to ketamine or dilaudid

- Deemed un-acceptable by study team

- Cognitively impaired (by history)

- Subject requires chronic antipsychotic medication

- Subject known to be in liver failure

- Subject for whom opioids or ketamine are contraindicated

- Patients with narrow angle glaucoma

- Patients with a history of psychosis

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ketamine
0.12 mg/kg/hr of ketamine post surgery
Saline
Saline will be administered at the same rate as the ketamine infusion.

Locations

Country Name City State
United States New York University School of Medicine New York New York

Sponsors (1)

Lead Sponsor Collaborator
New York University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Hydromorphone Use/24 Hours postOP in mg/kg Hydromorphone use during the first postoperative 24 hours in mg/kg 24 Hours
See also
  Status Clinical Trial Phase
Completed NCT04037059 - Impact of Body Habitus (Arm Span and Abdominal Girth) on Activities of Daily Living (ADL)
Recruiting NCT03883022 - Vancomycin Powder Combined With Autogenous Bone Graft as a Prevention for Post-operative Infection for Spine Surgery N/A
Not yet recruiting NCT06003010 - Yoga for Adolescent Idiopathic Scoliosis (AIS) Patients N/A
Completed NCT01136590 - Multicenter, Randomized Placebo-controlled Clinical Trial to Evaluate the Effect of Perioperative Use of Tranexamic Acid on Transfusion Requirements and Surgical Bleeding in Major Spine Surgery Phase 4
Completed NCT01235650 - Prevalence of Inadvertent Hyperventilation During Intraoperative Anesthetic Care N/A
Completed NCT03459404 - Sufentanil NanoTab PCA System/15 mcg for Acute Post-Operative Pain in Vertebral Surgery: A Preliminary Investigation
Recruiting NCT05010148 - A Clinical Trial of Intravenous Lidocaine After Spinal Surgery to Prevent Delirium and Reduce Pain Phase 3
Recruiting NCT04605120 - Allogeinic Bone Paste N/A
Completed NCT03826329 - Risk Factors of Second Surgery for Adjacent Segment Disease Following Anterior Cervical Discectomy and Fusion
Recruiting NCT04601363 - Personalized Spine Study Group (PSSG) Registry
Recruiting NCT05323448 - Efficacy of ARISTA-AH for Restoring Hemostasis Following Posterior Long-segment Spinal Fusion. N/A
Completed NCT00994656 - Is Pleth Variability Index (PVI) a Surrogate for Pulse Pressure Variations (PPV) in Pediatric Spine Fusion (SF) Surgery? N/A
Completed NCT00152152 - Use of Radiostereometric Analysis Beads (RSA) to Measure Motion in the Spine, Following Lumbar Spinal Surgery N/A
Terminated NCT03425799 - Efficacy and Safety of Tranexamic Acid in Spinal Fusion Surgery Phase 3
Not yet recruiting NCT06368245 - Durability of Suppl. Rod Constructs-SuppleMentAry Rod Technique for Long-segment Posterior Instrumented Spinal Fusions
Withdrawn NCT03908203 - Minimally Invasive Surgery Techniques for One-level Degenerative Lumbar Deformities Correction N/A
Terminated NCT03378973 - The Effects of Dexmedetomidine Dose on Motor Evoked Potentials Phase 4
Completed NCT05936047 - Bone Marrow Clot for Posterior Lumbar Fusion N/A
Not yet recruiting NCT03692845 - Minimally Invasive Versus Open Transforaminal Lumbar Interbody Fusion N/A
Completed NCT00152165 - Use of Radiostereometric Analysis (RSA) Following Spinal Fusion Versus the DYNESYS Stabilization System N/A